ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Martin Smollich, Martin Götte, Jeanett Fischgräbe, Luciana F. MacEdo, Angela Brodie, Shiuan Chen, Isabel Radke, Ludwig Kiesel, Pia Wülfing*
Dive into the research topics of 'ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole'. Together they form a unique fingerprint.